Skip to main
SPRB

SPRB Stock Forecast & Price Target

SPRB Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spruce Biosciences is poised for success based on strong physician feedback and its innovative product candidate, TA-ERT, which addresses a significant unmet medical need in MPS IIIB. With similar biomarker and clinical data to Avalayah, recent accelerated approval for a rare disorder, Spruce has adequate line of sight for its BLA submission in 4Q26 and a potential first-mover advantage in this white space market, with exclusive IP through 2037-2038 and market data supports $300M+ peak sales. Additionally, entering the market with a strong balance sheet, Spruce is well-positioned to become a cash flow generator for future pipeline development.

Bears say

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing therapies aimed at rare endocrine disorders. The company's lead candidate, TA-ERT, has shown promising results in clinical trials, but there are still uncertainties regarding regulatory approval and commercialization. With a limited pipeline and potential financial risks, the outlook for Spruce Biosciences may be negative.

SPRB has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spruce Biosciences Inc (SPRB) Forecast

Analysts have given SPRB a Strong Buy based on their latest research and market trends.

According to 9 analysts, SPRB has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $172.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $172.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spruce Biosciences Inc (SPRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.